Turkish Journal of Biology
Volume 38

Number 6

Article 9

1-1-2014

The role of ABC transporters in anticancer drug transport
SERHAN KARVAR

Follow this and additional works at: https://journals.tubitak.gov.tr/biology
Part of the Biology Commons

Recommended Citation
KARVAR, SERHAN (2014) "The role of ABC transporters in anticancer drug transport," Turkish Journal of
Biology: Vol. 38: No. 6, Article 9. https://doi.org/10.3906/biy-1407-3
Available at: https://journals.tubitak.gov.tr/biology/vol38/iss6/9

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Biology by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

Turkish Journal of Biology
http://journals.tubitak.gov.tr/biology/

Review Article

Turk J Biol
(2014) 38: 800-805
© TÜBİTAK
doi:10.3906/biy-1407-3

The role of ABC transporters in anticancer drug transport
Serhan KARVAR*
Division of Gastroenterology and Hepatology, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA
Received: 01.07.2014

Accepted: 10.09.2014

Published Online: 24.11.2014

Printed: 22.12.2014

Abstract: The main clinical problem in cancer treatment is the development of multidrug resistance. Tumors can be intrinsically drugresistant or develop resistance to chemotherapy. Multidrug resistance can develop by diverse mechanisms including decreased rate of
drug uptake, increased drug efflux, alterations in drug metabolism, mutation of drug targets, activation of DNA repair mechanisms,
and evasion of apoptosis. The use of modern genomic, proteomic, bioinformatic, and systems biology approaches has resulted in a
substantial increase in our ability to identify molecular mechanisms that are involved in multidrug resistance in cancer and to find drugs
that may block or reverse the development of drug resistance.
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1. Introduction
Initial chemotherapy of cancer may prove highly
beneficial, nearly annihilating a tumor, but a few resistant
cancer cells often survive and proliferate. Despite more
aggressive second and third courses of chemotherapy, the
remaining drug-resistant cells thrive, displaying increasing
resistance to drug therapy and eventually displaying virtual
invulnerability to chemotherapy. Chemotherapy may fail
because the remaining tumor cells are chemotherapyresistant. One of the main clinical issues in cancer is the
development of multidrug resistance (MDR) (Fletcher
et al., 2010). Malignant tumors usually consist of mixed
populations of cells, some of which are drug-sensitive while
others are drug-resistant. Chemotherapy leaves behind a
higher proportion of drug-resistant cells (Gottesman et al.,
2002; Albrecht and Viturro, 2007). MDR exists against every
anticancer drug and can develop by numerous mechanisms
including decreased drug uptake, increased drug efflux,
activation of detoxifying systems, activation of DNA repair
mechanisms, and evasion of drug-induced apoptosis
(Krishna and Mayer, 2000). A well-studied mechanism of
MDR involves the increased expression of members of the
ATP binding cassette (ABC) transporter superfamily, many
of which efflux various chemotherapeutic compounds,
leading to the decrease of intracellular drug levels and
consequent drug insensitivity (Ambudkar, 1999; Gottesman
et al., 2002; Shepard et al., 2003).
MDR transporters include ABCB1 (also known as
P-glycoprotein or MDR1), ABCC1 (also known as MRP1),
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and ABCG2 (also known as BCRP or MXR). The classic
resistance to chemotherapy drugs has most often been
linked to the overexpression of P-glycoprotein, an ATPdependent membrane transporter that acts as a drug efflux
pump (Table). The cytotoxic drugs that are most frequently
associated with MDR are hydrophobic, amphipathic
natural products, such as the taxanes (paclitaxel, docetaxel),
vinca alkaloids (vinorelbine, vincristine, vinblastine),
anthracyclines (doxorubicin, daunorubicin, epirubicin),
epipodophyllotoxins (etoposide, teniposide), topotecan,
dactinomycin, and mitomycin C (Ambudkar, 1999; Krishna
and Mayer, 2000).
2. ABC transporters
ABC transporters are transmembrane proteins that utilize
the energy of adenosine triphosphate (ATP) binding and
hydrolysis to carry a wide variety of xenobiotics (including
drugs), lipids, sterols, and metabolic products across the
plasma and intracellular membranes (Ambudkar, 1999;
Gottesman et al., 2002; Dean, 2005; Fletcher et al., 2010). The
ABC transporters are the largest family of transmembrane
proteins, with 7 subfamilies that are designated A to G on
the basis of sequence and structural homology. Human
ABC transporters are involved in several diseases that arise
from polymorphisms in ABC genes. Such diseases include
cystic fibrosis, adrenoleukodystrophy, Stargardt disease,
Tangier disease, Mendelian diseases, progressive familial
intrahepatic cholestasis, Dubin–Johnson syndrome,
pseudoxanthoma elasticum, X-linked sideroblastosis
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and anemia, age-related macular degeneration, familial
hypoapoproteinemia, and retinitis pigmentosum. The
human ABCB (MDR/TAP) family is responsible for MDR
against a variety of structurally unrelated drugs. ABCB1 or
MDR1 P-glycoprotein is also involved in other biological
processes for which lipid transport is the main function
(Albrecht and Viturro, 2007).
3. ABC transporters in cancer
Research is under way on many fronts to better understand
MDR in cancer and to find drugs that may block or reverse
the development of drug resistance in cancer cells. Studies
have found that P-glycoprotein, called the multidrug
transporter, is expressed in increased amounts as a result
of genetic alterations in cells to build their resistance to
many anticancer drugs (Thomas and Coley, 2003). Genetic
and molecular studies have shown that, in humans, these
multidrug-resistant cells contain amplified MDR1 genes,
resulting in increased gene expression. The MDR1a gene,
which encodes P-glycoprotein, is expressed at significant
levels in about half of all human cancers (Weinstein, 1991;
Abolhoda et al., 1999; Zochbauer-Muller, 2001; Mochida,
2003; Yamada, 2003; Szakacs, 2004; Yoh, 2004; Konig,
2005; Oda, 2005; Haber, 2006; Oberthuer, 2006; Steinbach,
2006; Maris et al., 2007; Ohtsuki, 2007; Hanada, 2008;
Oevermann, 2009; Vander Borght, 2008). The multidrug
transporter is 1 of 2 major mechanisms identified in the
efflux, or extraction, of drugs from animal cells. The other
mechanism for drug efflux involves expression of a gene
known as the multidrug resistance associated protein
(MRP). Both the MDR1 and the MRP genes are members
of a superfamily of ATP-dependent transporters. There are
probably other, unidentified members of this superfamily

that are involved in other forms of drug resistance (Fletcher
et al., 2010; Holohan et al., 2013).
The etiology of MDR may be multifactorial, but
the classic resistance to the cytotoxic drugs mentioned
above has most often been linked to the overexpression
of P-glycoprotein, a 170-kDa ATP-dependent membrane
transporter that acts as a drug efflux pump (Gottesman
et al., 2002). These transporters use the energy that is
released when they hydrolyze ATP to drive the transport
of various molecules across the cell membrane. In addition
to their physiologic expression in normal tissues, many
are expressed and, importantly, overexpressed in human
tumors (Thomas and Coley, 2003; Fletcher et al., 2010;
Holohan et al., 2013). A number of ABC transporters and
the chemotherapy drugs to which they have been shown to
confer resistance are listed in the Table.
In cancerous tissue, the expression of P-glycoprotein
is usually highest in tumors that are derived from tissues
that normally express P-glycoprotein, such as epithelial
cells of the colon, kidney, adrenal, pancreas, and liver,
resulting in the potential for resistance to some cytotoxic
agents before chemotherapy is initiated (Weinstein, 1991;
Abolhoda et al., 1999; Zochbauer-Muller, 2001; Mochida,
2003; Yamada, 2003; Szakacs, 2004; Yoh, 2004; Konig,
2005; Oda, 2005; Haber, 2006; Oberthuer, 2006; Steinbach,
2006; Maris et al., 2007; Ohtsuki, 2007; Hanada, 2008;
Oevermann, 2009; Vander Borght, 2008). In other tumors,
the expression of P-glycoprotein may be low at the time
of diagnosis but increases after exposure to chemotherapy
agents, thereby resulting in the development of MDR
in those cells. There is a growing body of literature that
links the failure of certain chemotherapeutic agents to the
expression of P-glycoprotein ( Thomas and Coley, 2003;

Table. Human ABC transporters subfamilies and their functions in cancer.
ABC family

Function

ABCA

Responsible for the transportation of estramustine, mitoxantrone, and anthracyclines.

ABCB

Responsible for the transportation of colchicine, anthracyclines, epipodophyllotoxins, vinca alkaloids, taxanes,
camptothecins, bisantrene, imatinib, mitoxantrone, saquinivir, methotrexate, camptothecins,
thiopurines, and actinomycin D. Some are located in the blood–brain barrier, liver, mitochondria, transport peptides,
and bile.

ABCC

Responsible for the transportation of anthracyclines, camptothecins, cisplatin, colchicine, epipodophyllotoxins,
imatinib, methotrexate, mitoxantrone, taxanes, thiopurines, and vinca alkaloids.

ABCD

ABCD transporters are involved in peroxisomal import of fatty acids in the organelle.

ABCE/ABCF

These are not actually transporters but merely ATP-binding domains that were derived from the ABC family, without
the transmembrane domains. These proteins mainly regulate protein synthesis.

ABCG

Transports anthracyclines, bisantrene, camptothecins, epipodophyllotoxins, lipids, flavopiridol, imatinib,
methotrexate, mitoxantrone, bile, cholesterol, and other steroids.
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Fletcher et al., 2010; Holohan et al., 2013). Indeed, the
induction of MDR1 RNA can be rapid following exposure
of tumor cells to chemotherapy. Inhibiting P-glycoprotein
as a way of reversing MDR has been extensively studied.
Many agents that modulate the function of P-glycoprotein
have been identified, including calcium channel blockers,
calmodulin antagonists, steroidal agents, protein kinase
C inhibitors, immunosuppressive drugs, antibiotics, and
surfactants (Ferry et al., 1996).
4. Targeting drug resistance in cancer
MDR may result from a variety of cellular adaptations
including reduced drug uptake, increased energydependent drug efflux, altered response to drugs because
of changes in programmed cell death (apoptosis), and
altered cellular metabolism or sequestering of drugs
within cellular compartments (summarized in the Figure).
Multidrug resistance can be intrinsic (cancers do not
respond to any chemotherapy) or acquired (tumors
respond, sometimes dramatically, but eventually grow

back and are resistant to subsequent therapy) ( Krishna
and Mayer, 2000; Gottesman et al., 2002; Albrecht and
Viturro, 2007; Fletcher et al., 2010).
In most tissue culture studies of anticancer drug
resistance, a predominant mechanism of both forms
of MDR is the overexpression of an energy-dependent
transporter known as P-glycoprotein, the product of the
MDR1 or ABCB1 gene (Gottesman et al., 2002; Fletcher et
al., 2010). This protein is a transmembrane transporter that
resides in the plasma membrane of many cells, including
cancer cells that are multidrug-resistant. P-glycoprotein
recognizes a wide range of anticancer drugs, many of
which are water-insoluble (lipophilic) natural products
from plants such as vinca alkaloids, paclitaxel, and fungal
products such as anthracyclines and actinomycin D, and
keeps these drugs from accumulating at levels sufficient to
kill the cell. P-glycoprotein is a member of a family of ATPdependent transporters found in all living organisms that
are called ABC (for ATP-binding cassette) transporters (
Dean et al., 2001; Dean, 2005; Dean, 2009). In the human,

Figure. Molecular mechanisms of drug resistance. Cancer drug resistance can occur
by many mechanisms, including poor drug influx, increased drug efflux, increased
intracellular drug accumulation, increased drug inactivation or lack of activation;
alterations such as changes in expression levels of the drug target; activation of
adaptive prosurvival responses; and a lack of cell death induction due to dysfunctional
apoptosis.
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there are multiple transporters, and many are involved in
the transport of lipophilic substances, such as cholesterol
and phospholipids, into cellular organelles and out of the
cell. A few of these transporters, notably ABCB1, ABCC1,
and ABCG2, can pump a broad range of small molecules,
many of which are used to treat cancer, and they have also
been found to confer MDR to cancer cells. Several lines of
evidence suggest that, among these, ABCB1 is most likely
to be associated with clinical MDR in cancer, including
multiple myeloma, certain types of leukemia, breast
cancer, and ovarian cancer (Thomas and Coley, 2003).
Since P-glycoprotein alone can mediate resistance to a
whole array of drugs through drug efflux, it is an attractive
target for the improvement of anticancer therapy (Ferry
et al., 1996; Krishna and Mayer, 2000). Loss of the abcb1
genes in mice (equivalent to the human ABCB1 gene)
is compatible with life and does not result in an overt
phenotype (Schinkel, 1994; Schinkel et al., 1997). These
results have been interpreted to suggest that P-glycoprotein
inhibitors would likely be safe for human use. Clinical
trials aimed at specifically inhibiting the function of
P-glycoprotein have given mixed results, but in at least
some cases this inhibition has resulted in improved tumor
shrinkage and increased patient survival. Unfortunately,
P-glycoprotein inhibitors such as PSC-833 (valspodar)
induced pharmacokinetic interactions that limited
drug clearance and metabolism of the concomitantly
administered chemotherapy, thereby elevating plasma
concentrations beyond acceptable toxicity (Greenberg,
2004; Lhomme, 2008). The solid tumors that have proved
particularly intractable, including colon, liver, kidney,
and pancreatic cancers, tend to express ABCB1, but are
probably also protected by many other mechanisms of
drug resistance, so simple intervention by inhibition
of ABCB1 has not proved beneficial in treating those
particular tumors (Relling, 1996; Garraway and Chabner,
2002; Thomas and Coley, 2003; Szakacs, 2004; Fletcher et
al., 2010).
The major limitation of the early agents is that they
typically reverse MDR at concentrations that result in high
toxicity. This, together with unfavorable pharmacokinetic
interactions, prompted the development of a number
of new molecules that are more potent and selective
for the P-glycoprotein transporter (Thomas and Coley,
2003; Fletcher et al., 2010). These agents often produced
disappointing results in vivo because their low binding
affinities necessitated the use of high doses, resulting in
high toxicity (Ferry et al., 1996; Krishna and Mayer, 2000;
Thomas and Coley, 2003). Many of the first chemosensitizers
identified were themselves substrates for P-glycoprotein and
thus worked by competing with the cytotoxic compounds
for efflux by the P-glycoprotein pump; therefore,

high serum concentrations of the chemosensitizers
were necessary to produce adequate intracellular
concentrations of the cytotoxic drug (Ambudkar,
1999). In addition, many of these chemosensitizers are
substrates for other transporters and enzyme systems,
resulting in unpredictable pharmacokinetic interactions
in the presence of chemotherapy agents. To overcome
these limitations, several novel analogs of these early
chemosensitizers were tested and developed, with the aim
of finding P-glycoprotein modulators with less toxicity
and greater potency (Krishna and Mayer, 2000). The
second-generation P-glycoprotein modulators include
dexverapamil, dexniguldipine, valspodar (PSC 833), and
biricodar (VX-710). These agents are more potent than
their predecessors and also less toxic (Krishna and Mayer,
2000; Baekelandt et al., 2001; Fracasso et al., 2001; Advani
et al., 2005). The best characterized and most studied
of these agents is valspodar, a nonimmunosuppressive
derivative of cyclosporin D that inhibits P-glycoprotein
with 10- to 20-fold greater activity than cyclosporin A
(Twentyman and Bleehen, 1991; te Boekhorst et al., 1992).
The third-generation P-glycoprotein inhibitors currently
in development include the anthranilamide derivative
tariquidar (XR9576), the cyclopropyldibenzosuberane
zosuquidar (LY335979), laniquidar (R101933), and the
substituted diarylimidazole ONT-093 (Dantzig et al.,
1996; Starling et al., 1997; Dantzig et al., 1999; Roe et
al., 1999; Newman et al., 2000; van Zuylen et al., 2000;
Maliepaard et al., 2001; Mistry et al., 2002). These agents
have in common a high potency and specificity for the
P-glycoprotein transporter. The modulator elacridar
(GF120918/GG918), while not as P-glycoprotein -specific
as agents such as tariquidar, has been shown to inhibit
breast cancer resistance protein BCRP (Maliepaard et al.,
2001).
5. Conclusions
Much remains unknown about the fundamental biology
of cancers, and although many of the molecular pathways
of cancer drug resistance have now been elucidated, new
effective targeted agents have yet to be introduced into
clinical practice. As for mechanisms by which cancer
cells become malignant, each tumor will have a unique
signature of resistance mechanisms. The use of powerful
high-throughput techniques such as microarray profiling,
proteomics and next-generation sequencing provide
data that can be used to identify potential predictive
biomarkers for patient selection. Therapy will need to be
personalized with respect to mechanisms of resistance.
The continued development of new agents may establish
the true therapeutic potential of P-glycoprotein-mediated
MDR reversal.
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